Kairos Pharma Ltd./$KAPA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kairos Pharma Ltd.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Ticker
$KAPA
Sector
Primary listing
AMEX
Employees
3
Headquarters
Website
KAPA Metrics
BasicAdvanced
$35M
-
-$0.33
-
-
Price and volume
Market cap
$35M
52-week high
$2.11
52-week low
$0.40
Average daily volume
1.4M
Financial strength
Current ratio
7.158
Quick ratio
4.488
Interest coverage (TTM)
-35.83%
Profitability
EBITDA (TTM)
-4.391
Management effectiveness
Return on assets (TTM)
-73.85%
Return on equity (TTM)
-281.84%
Valuation
Price to book
4.97
Price to tangible book (TTM)
5.09
Price to free cash flow (TTM)
-4.475
Free cash flow yield (TTM)
-22.35%
Free cash flow per share (TTM)
-0.375
Growth
Earnings per share change (TTM)
73.25%
KAPA News
AllArticlesVideos
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
Business Wire11 hours ago
Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
Business Wire1 week ago
Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kairos Pharma Ltd. stock?
Kairos Pharma Ltd. (KAPA) has a market cap of $35M as of September 18, 2025.
What is the P/E ratio for Kairos Pharma Ltd. stock?
The price to earnings (P/E) ratio for Kairos Pharma Ltd. (KAPA) stock is 0 as of September 18, 2025.
Does Kairos Pharma Ltd. stock pay dividends?
No, Kairos Pharma Ltd. (KAPA) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Kairos Pharma Ltd. dividend payment date?
Kairos Pharma Ltd. (KAPA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kairos Pharma Ltd.?
Kairos Pharma Ltd. (KAPA) does not currently have a Beta indicator.